KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $851.0 million.

  • Sarepta Therapeutics' Cash & Current Investments fell 2898.67% to $851.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $851.0 million, marking a year-over-year decrease of 2898.67%. This contributed to the annual value of $1.4 billion for FY2024, which is 4828.58% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Cash & Current Investments of $851.0 million as of Q3 2025, which was down 2898.67% from $963.0 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Cash & Current Investments registered a high of $2.6 billion during Q4 2023, and its lowest value of $851.0 million during Q3 2025.
  • Over the past 5 years, Sarepta Therapeutics' median Cash & Current Investments value was $1.7 billion (recorded in 2023), while the average stood at $1.7 billion.
  • In the last 5 years, Sarepta Therapeutics' Cash & Current Investments surged by 3168.8% in 2023 and then plummeted by 4828.58% in 2024.
  • Sarepta Therapeutics' Cash & Current Investments (Quarter) stood at $2.1 billion in 2021, then fell by 5.98% to $2.0 billion in 2022, then soared by 31.69% to $2.6 billion in 2023, then tumbled by 48.29% to $1.4 billion in 2024, then crashed by 37.18% to $851.0 million in 2025.
  • Its last three reported values are $851.0 million in Q3 2025, $963.0 million for Q2 2025, and $894.2 million during Q1 2025.